Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
747.30
-4.95 (-0.66%)
Streaming Delayed Price
Updated: 11:42 AM EDT, Sep 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
66
67
Next >
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
↗
February 02, 2024
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system.
Via
Benzinga
Topics
Economy
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
↗
February 02, 2024
The Dow led the major indexes higher. Big techs diverged on results.
Via
Investor's Business Daily
Topics
Economy
Stocks
Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today?
↗
February 02, 2024
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77.
Via
Benzinga
Earnings Outlook For Regeneron Pharmaceuticals
↗
February 01, 2024
Via
Benzinga
Breaking Down Regeneron Pharmaceuticals: 14 Analysts Share Their Views
↗
January 29, 2024
Via
Benzinga
The Surprising Sources Of Regeneron's Fourth-Quarter Beat As Shares Hit Another Record High
↗
February 02, 2024
Shares usually rally on Eylea news, but Regeneron stock is on the rise following fourth-quarter beats from two other products.
Via
Investor's Business Daily
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
↗
February 02, 2024
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc.
Via
Benzinga
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
February 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
February 02, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For February 2, 2024
↗
February 02, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion.
Via
Benzinga
3 Top Pharma Stocks to Buy Now: February 2024
↗
February 01, 2024
Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.
Via
InvestorPlace
Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.
↗
February 01, 2024
The company missed total sales and earnings expectations.
Via
Investor's Business Daily
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
January 30, 2024
Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
↗
January 29, 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.
Via
Benzinga
Topics
Artificial Intelligence
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
↗
January 29, 2024
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending.
Via
Benzinga
Topics
Artificial Intelligence
3 Magnificent Stocks to Buy and Hold Forever
↗
January 27, 2024
Many investors will want to consider owning these stocks for a long time.
Via
The Motley Fool
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
↗
January 26, 2024
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.
Via
Benzinga
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
January 25, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
↗
January 24, 2024
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.
Via
Benzinga
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
January 24, 2024
Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
↗
January 23, 2024
Blue-chip healthcare stocks combine stability, profitability, and long-term growth prospects into a single investable package.
Via
InvestorPlace
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) Sets New 52-Week High in Tuesday Session
January 23, 2024
Via
Investor Brand Network
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
↗
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
↗
January 22, 2024
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Via
Benzinga
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
↗
January 21, 2024
These businesses are on paths to extremely bright futures.
Via
The Motley Fool
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
↗
January 18, 2024
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.
Via
Benzinga
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
↗
January 18, 2024
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Via
Investor's Business Daily
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
↗
January 16, 2024
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.
Via
InvestorPlace
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
January 16, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
↗
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
< Previous
1
2
...
30
31
32
33
34
35
36
37
38
...
66
67
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
